Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.
We recently traveled to New York City, New York, for a State of the Science Summit™ on Breast Cancer, where we spoke with Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center, and assistant attending surgeon, NewYork-Presbyterian, and Alan B. Astrow, MD, a professor of clinical medicine at Weill Cornell Medicine, and chief of hematology and medical oncology, at New York Methodist Hospital. In our discussion, Drs Newman and Astrow discussed the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor—positive, HER2-negative breast cancer.
First, we heard from Dr Newman, who presents a case of a 41-year-old premenopausal woman with a strong family history of breast cancer. On routine screening, the patient was found to have a density in the left breast with which an initial image-guided core-needle biopsy revealed a radial scar lesion. After undergoing a diagnostic surgical biopsy, she was found to have microinvasive triple-negative breast cancer. Listen on to hear the complete case presentation from Dr. Newman and the doctors’ recommendations for treatment.
Next, we heard from Dr Astrow, who presents a case of a 43-year-old premenopausal woman with a 9.5-millimeter grade 2 infiltrating ductal carcinoma. The cancer is estrogen receptor— and progesterone receptor–positive and HER2-negative. The patient’s Ki-67 is 20% and her sentinel node is negative. Listen on to hear the complete case presentation from Dr. Astrow and the doctors’ approach to treatment.
That’s all we have for today! Thank you for listening to OncLive On Air. Check back on Wednesdays for new interviews from our State of the Science Summits™.
Interested in attending an upcoming OncLive® State of the Science Summit™ in your area? Register today.